| Product Name |
Recombinant Human Ferritin, Light Polypeptide (FTL) Protein |
| Product Overview |
This recombinant human Ferritin, Light Polypeptide (FTL) protein includes amino acids 2-175aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
P02792 |
| Recommended Name |
Ferritin light chain |
| Gene Name |
FTL |
| Synonyms |
Ferritin, light polypeptide, Ferritin L subunit |
| Species |
Human |
| Predicted Molecular Mass |
23.6 kDa |
| Expression System |
E.coli |
| Expression Range |
2-175aa |
| Tag |
N-6His |
| Purity |
>95% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Cardiovascular |
| Target Function |
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney. |
| Protein Family |
Ferritin family |
| Associated Diseases |
Hyperferritinemia with or without cataract (HRFTC); Neurodegeneration with brain iron accumulation 3 (NBIA3); L-ferritin deficiency (LFTD) |
